Two recent phase 2 trials of vandetanib in RET-rearranged NSCLC

Affiliations

¹ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea. Electronic address: shlee119@skku.edu.
² Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.

Comment

Se-Hoon Lee et al. Lancet Respir Med. 2017 Feb.

. 2017 Feb;5(2):e10.

doi: 10.1016/S2213-2600(17)30010-3.

¹ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, South Korea. Electronic address: shlee119@skku.edu.
² Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, South Korea.

No abstract available

Comment on

Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.
Yoh K, Seto T, Satouchi M, Nishio M, Yamamoto N, Murakami H, Nogami N, Matsumoto S, Kohno T, Tsuta K, Tsuchihara K, Ishii G, Nomura S, Sato A, Ohtsu A, Ohe Y, Goto K. Yoh K, et al. Lancet Respir Med. 2017 Jan;5(1):42-50. doi: 10.1016/S2213-2600(16)30322-8. Epub 2016 Nov 4. Lancet Respir Med. 2017. PMID: 27825616 Clinical Trial.